Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Tysabri (natalizumab)-Important Safety Information from Elan/Biogen Idec as approved by the Arcoxia (etoricoxib)-Important Safety Information from Merck Sharp & Dohme following approval by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
18/08/2008
Problem Or Issue:
Please find herewith an important safety communication on the association of natalizumab (Tysabri) with progressive multifocal leukoencephalopathy (PML).
« Back
Date Printed: 11/05/2024